share_log

Blueprint Medicines | 8-K: Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT® / AYVAKYT ® (avapritinib) Full Year Revenue Guidance

Blueprint Medicines | 8-K: Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT® / AYVAKYT ® (avapritinib) Full Year Revenue Guidance

Blueprint Medicines | 8-K:Blueprint Medicinib 公佈2024年第三季度業績並上調了AYVAKIT® /AyvaKYT®(avapritinib)全年收入指引
美股SEC公告 ·  10/30 19:11
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息